arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Rallybio Corp

RLYB
$16.89 ▼ -0.02 (-0.15%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
27 Visible periods
22 Metrics
Peer-ranked Benchmarks
Price Chart
48
Health
Weak
Neutral
auto_awesome

Analytical Summary

Rallybio Corp shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $96.3M
Dividend Yield —
Revenue Growth N/M
Op. Margin —
ROIC -4.7% ↗
FCF / Share $8.06 ↗
Trailing P/E 2.2x
Price / Book 1.0x
FCF Yield 47.7%
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
↓ -100.0% —
Net Income Profit after all expenses
$43.66M
↑ +627.5% —
FCF / Share Free cash flow per share
$8.06
↑ +674.5% —

Health Breakdown

Returns ↑
30
Cash Quality ↑
92

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 27 quarters